Merdeka.com – Johnson & Johnson’s JNJ.N Covid-19 vaccine, known as the Ad26.COV2.S vaccine, is one of the many proposed coronavirus vaccines and has produced a strong immune response in trial participants. This vaccine is called unique because it is given in one injection, not in two doses.
Citing the page of The Independent, Sunday (27/9), Johnson & Johnson’s JNJ.N Covid-19 vaccine was well tolerated by subjects at two sample doses in early to intermediate stages of the corona virus clinical trial.
It is the only third-phase Covid-19 vaccine trial in the United States that is testing a single-dose vaccine.
The researchers said 98 percent of the participants in the study for which data were available had neutralizing antibodies, which help the body fight pathogens a month after they received the vaccine.
Nearly 1,000 healthy adults are participating in a clinical trial that began after Johnson & Johnson saw that the vaccine provided strong immune protection when tested on monkeys.
The company started its latest pilot phase on Wednesday when it was tested on 60,000 people. If the results are successful, then this will be another step on the road to a viable coronavirus vaccine.
Although the results so far are promising, researchers’ attention remains on whether or not the vaccine will be effective in older people.
these were well tolerated by subjects at two sample doses in early to intermediate clinical trials of coronavirus.
It is the only third-phase Covid-19 vaccine trial in the United States that is testing a single-dose vaccine.
The researchers said 98 percent of the participants in the study for which data were available had neutralizing antibodies, which help the body fight pathogens a month after they received the vaccine.
–
Nearly 1,000 healthy adults are participating in a clinical trial that began after Johnson & Johnson saw that the vaccine provided strong immune protection when tested on monkeys.
The company started its latest pilot phase on Wednesday when it was tested on 60,000 people. If the results are successful, then this will be another step on the road to a viable coronavirus vaccine.
Although the results so far are promising, researchers’ attention remains on whether or not the vaccine will be effective in older people.
Participants over the age of 65 reported adverse reactions to the drug, such as fatigue and muscle aches, but only 36 percent. Meanwhile, younger participants reported this effect at the 64 percent level. Because older patients don’t experience side effects as often as possible, the researchers worry they may not have the same immune response as other people.
Only 15 percent included in the report were over the age of 65. Johnson & Johnson also said that trials should be completed by the end of the year or early 2021.
Reporter Magang: Galya Nge
[pan]– .
